Familial Cancer

, Volume 10, Issue 1, pp 59–63 | Cite as

Two BRCA1/2 founder mutations in Jews of Sephardic origin

  • Michal Sagi
  • Avital Eilat
  • Liat Ben Avi
  • Yael Goldberg
  • Dani Bercovich
  • Tamar Hamburger
  • Tamar Peretz
  • Israela Lerer
Article

Abstract

Founder mutations in BRCA1/2 genes have been detected in several Jewish communities in Israel, including in Ashkenazi Jews and Jews who immigrated to Israel from Iraq, Yemen, Iran and Afghanistan. We analyzed DNA samples of patients of Sephardic origin (descendents of Jews from the Iberian Peninsula) with breast cancer (BC) and/or ovarian cancer (OC) and additional family history of these cancers. In this study we identified 2 mutations: p.A1708E in BRCA1 and c.67 + 1G > A (IVS2 + 1G > A) in BRCA2, each in 3 unrelated patients. The frequency of the two mutations was 26–31% among Sephardic high risk families and about 3% among the full cohort of 177 patients of this origin who were tested in our center. Based on haplotype analysis we concluded that these mutations are most probably founder mutations in Sephardic Jews. We recommend testing the two mutations in women of Sephardic origin who apply for BRCA testing because of personal and/or family history of BC and/or OC. Furthermore, we suggest adding them to the 5 mutations included in “The Jewish panel” of BRCA1/2 mutations that are being tested in Israel.

Keywords

BRCA1/2 DHPLC Founder mutations Sephardic Jews 

References

  1. 1.
    Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60:505–514PubMedGoogle Scholar
  2. 2.
    Lerer I, Wang T, Peretz T, Sagi M, Kaduri L, Orr-Urtreger A, Stadler J, Gutman H, Abeliovich D (1998) The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet 63:272–274CrossRefPubMedGoogle Scholar
  3. 3.
    Shiri-Sverdlov R, Gershoni-Baruch R, Ichezkel-Hirsch G, Gotlieb WH, Bruchim Bar-Sade R, Chetrit A, Rizel S, Modan B, Friedman E (2001) The Tyr978X BRCA1 Mutation in Non-Ashkenazi Jews: Occurrence in High-Risk Families, General Population and Unselected Ovarian Cancer Patients. Community Genet 4:50–55CrossRefPubMedGoogle Scholar
  4. 4.
    Ben-Sasson HH (ed) (1976) A history of the Jewish People. Harvard University Press, Cambridge, MassachusettsGoogle Scholar
  5. 5.
    Bercovich D, Beaudet AL (2003) Denaturing high-performance liquid chromatography for the detection of mutations and polymorphisms in UBE3A. Genet Test 7:189–194CrossRefPubMedGoogle Scholar
  6. 6.
    Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A (2007) Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 18(Suppl 6):vi93–vi98Google Scholar
  7. 7.
    Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, Brøndum-Nielsen K, Gerdes AM, Møller P, Kristoffersson U, Olsson H, Borg A, Monteiro AN (2001) Functional analysis of BRCA1 C terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 10:353–560CrossRefPubMedGoogle Scholar
  8. 8.
    Lovelock PK, Spurdle AB, Mok MT, Farrugia DJ, Lakhani SR, Healey S, Arnold S, Buchanan D, kConFab Investigators, Couch FJ, Henderson BR, DE Goldgar, Tavtigian SV, Chenevix-Trench G, Brown MA (2007) dentification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Res 9:R82CrossRefPubMedGoogle Scholar
  9. 9.
    de la Hoya M, Osorio A, Godino J, Sulleiro S, Tosar A, Perez-Segura P, Fernandez C, Rodríguez R, Díaz-Rubio E, Benítez J, Devilee P, Caldés T (2002) Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. Int J Cancer 97:466–471CrossRefPubMedGoogle Scholar
  10. 10.
    Infante M, Durán M, Esteban-Cardeñosa E, Miner C, Velasco E (2006) High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-León (central Spain). J Hum Genet 51:611–617CrossRefPubMedGoogle Scholar
  11. 11.
    Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, Tawil M, Torregrosa L, Briceno I, Hamann U (2007) High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat 103:225–232CrossRefPubMedGoogle Scholar
  12. 12.
    Bonatti F, Pepe C, Tancredi M, Lombardi G, Aretini P, Sensi E, Falaschi E, Cipollini G, Bevilacqua G, Caligo MA (2006) RNA-based analysis of BRCA1 and BRCA2 gene alterations. Cancer Genetics and Cytogenetics 170:93–101CrossRefPubMedGoogle Scholar
  13. 13.
    Breast Cancer Information Core:http://www.genome.gov/
  14. 14.
    Cohen T, Vardi-Saliternik R, Friedlander Y (2004) Consanguinity, intracommunity and intercommunity marriages in a population sample of Israeli Jews. Ann Hum Biol 31:38–48CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Michal Sagi
    • 1
  • Avital Eilat
    • 1
  • Liat Ben Avi
    • 1
  • Yael Goldberg
    • 2
  • Dani Bercovich
    • 3
  • Tamar Hamburger
    • 2
  • Tamar Peretz
    • 2
  • Israela Lerer
    • 1
  1. 1.Department of Human Genetics & Metabolic DiseasesHadassah Hebrew University Medical CenterJerusalemIsrael
  2. 2.Sharett institute of OncologyHadassah Hebrew University Medical CenterJerusalemIsrael
  3. 3.The Human Molecular Genetics, Migal - Galilee Bio-Technology Center, Kiryat-ShmonaIsrael and Tel Hai Academic CollegeTel HaiIsrael

Personalised recommendations